Tiratricol FDA approval: targets and potency in BioQ
Tiratricol FDA approval (Emcitate): ChEMBL shows 68 targets, THRB and THRA top by pChEMBL, and 3 registered trials on ClinicalTrials.gov, as of 2026-11-17.
BioQ Blog
Every BioQ post about ClinicalTrials.gov: real search results, sources and the query to repeat it.
Tiratricol FDA approval (Emcitate): ChEMBL shows 68 targets, THRB and THRA top by pChEMBL, and 3 registered trials on ClinicalTrials.gov, as of 2026-11-17.
NCT07877584 is a phase 3 NSCLC trial of PD-1 blockade with or without chemotherapy; BioQ adds carboplatin ChEMBL potency and ClinicalTrials.gov context.
A new FAERS paper on semaglutide and panic attacks, set against ChEMBL potency, ClinicalTrials.gov registrations and PubChem identity as of 2026-11-15.
NCT07821684 is a phase 3 trial in non-squamous NSCLC; we pair it with docetaxel potency in ChEMBL, 1628 registered trials and EGFR dependency in DepMap.
NCT07905456 is a PHASE2 gingivitis trial starting 2026-12-01; we checked chlorhexidine in ChEMBL (104 targets) and ClinicalTrials.gov (101 studies).
NCT06966843 tests dantrolene in statin-induced myopathy; BioQ pulls its ChEMBL potency and 7 registered dantrolene trials, data as of 2026-11-11.
NCT07916844 tests hepatic arterial infusion chemotherapy versus capecitabine in resected biliary tract cancer; ChEMBL and 1231 oxaliplatin studies.
NCT07885397 tests sonrotoclax in high-risk MDS; ChEMBL potency and 35 ClinicalTrials.gov studies show what is already known about the drug and its target.
NCT07879612 tests semaglutide in Cannabis Use Disorder; BioQ pulls GLP1R potency from ChEMBL and 349 semaglutide trials from ClinicalTrials.gov.
Phase 2 trial NCT07728851 tests nebulized ketamine in children with acute asthma; BioQ adds ChEMBL potency data and 682 registered ketamine trials.
One query, osimertinib, returns phase counts for 188 registered ClinicalTrials.gov studies and a status table, with EGFR drug context, as of 2026-11-06.
NCT07895017 tests avatrombopag around CAR T-cell therapy; BioQ adds ChEMBL potency, 38 registered avatrombopag trials and compound identity, as of 2026-11-06.